- Home
- NFJ vs NUVB Comparison
NFJ vs NUVB Comparison
Compare NFJ & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- NUVB
- Stock Information
- Founded
- NFJ 2005
- NUVB 2018
- Country
- NFJ United States
- NUVB United States
- Employees
- NFJ N/A
- NUVB N/A
- Industry
- NFJ Finance: Consumer Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- NUVB Health Care
- Exchange
- NFJ Nasdaq
- NUVB Nasdaq
- Market Cap
- NFJ 1.2B
- NUVB 1.1B
- IPO Year
- NFJ N/A
- NUVB N/A
- Fundamental
- Price
- NFJ $12.82
- NUVB $5.15
- Analyst Decision
- NFJ
- NUVB Strong Buy
- Analyst Count
- NFJ 0
- NUVB 7
- Target Price
- NFJ N/A
- NUVB $8.43
- AVG Volume (30 Days)
- NFJ 223.5K
- NUVB 8.2M
- Earning Date
- NFJ 01-01-0001
- NUVB 11-03-2025
- Dividend Yield
- NFJ 9.01%
- NUVB N/A
- EPS Growth
- NFJ N/A
- NUVB N/A
- EPS
- NFJ N/A
- NUVB N/A
- Revenue
- NFJ N/A
- NUVB $14,355,000.00
- Revenue This Year
- NFJ N/A
- NUVB $283.91
- Revenue Next Year
- NFJ N/A
- NUVB $340.13
- P/E Ratio
- NFJ N/A
- NUVB N/A
- Revenue Growth
- NFJ N/A
- NUVB 900.35
- 52 Week Low
- NFJ $10.45
- NUVB $1.54
- 52 Week High
- NFJ $12.86
- NUVB $5.55
- Technical
- Relative Strength Index (RSI)
- NFJ 42.18
- NUVB 76.51
- Support Level
- NFJ $12.81
- NUVB $3.36
- Resistance Level
- NFJ $13.04
- NUVB $5.55
- Average True Range (ATR)
- NFJ 0.16
- NUVB 0.32
- MACD
- NFJ -0.02
- NUVB 0.14
- Stochastic Oscillator
- NFJ 8.33
- NUVB 87.44
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.